Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 601–700 of 1,000
Gaffen, S. L., Herzberg, M. C., Taubman, M. A., & Dyke, T. E. V. (2014) · Advances in Dental Research · doi:10.1177/0022034514525778 · Cited by 19
A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis
Liu, C., Zhao, Y., He, W. Z., Wang, W., Chen, Y., Zhang, S., Ma, Y., Gohda, J., Ishida, T., Walter, T. S., et al. (2015) · Scientific Reports · doi:10.1038/srep14150 · Cited by 18
Goodwin, J. S., Zhou, J., Kuo, Y., & Baillargeon, J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.015 · Cited by 20
Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice
Moon, N., Effiong, L., Song, L., Gardner, T. R., & Soung, D. Y. (2018) · Nutrients · doi:10.3390/nu11010063 · Cited by 18
Disorders of mineral homeostasis in children and adolescents
Root, A. W., & Diamond, F. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00027-5 · Cited by 22
Nazari‐Farsani, S., Vuopio, M., Löyttyniemi, E., & Aro, H. T. (2021) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2021.110262 · Cited by 18
Denosumab – an emerging treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604708 · Cited by 21
Self-citationWong‐Pack, M., Kalani, A., Hordyk, J., Ioannidis, G., Bensen, R., Bensen, W., Παπαϊωάννου, Α., Adachi, J. D., & Lau, A. N. (2016) · Journal of Osteoporosis · doi:10.1155/2016/7903128 · Cited by 17
Yang, J., Guo, X., Cui, Z., Guo, H., & Dong, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431676 · Cited by 20
Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate
Lu, K., Wang, S., & Yang, S. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf013 · Cited by 17
Denosumab: A novel antiresorptive drug for osteoporosis
Suresh, E., & Abrahamsen, B. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.13173 · Cited by 21
Gowder, S. J. (2012) · InTech eBooks · doi:10.5772/3194 · Cited by 17
Denosumab in Postmenopausal Women With Low Bone Mineral Density
Pillinger, M. H. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70348-1 · Cited by 17
Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Kim, S. Y., Ok, H.-G., Birkenmaier, C., & Kim, K.-H. (2017) · The Korean journal of pain · doi:10.3344/kjp.2017.30.2.86 · Cited by 17
Neoadjuvant denosumab for the treatment of a sacral osteoblastoma
Reynolds, J., Rothenfluh, D. A., Athanasou, N. A., Wilson, S. R., & Kieser, D. (2018) · European Spine Journal · doi:10.1007/s00586-018-5461-z · Cited by 17
Bone Cell Communication Factors Provide a New Therapeutic Strategy for Osteoporosis
Kim, J. H., & Kim, N. (2020) · Chonnam Medical Journal · doi:10.4068/cmj.2020.56.2.94 · Cited by 18
The role of vitamin D receptor genes (FOKI and BSMI) polymorphism in osteoporosis
Mansour, L. A., Sedky, M. M., AbdelKhader, M., Sabry, R., Kamal, M., & Elsawah, H. (2010) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2010.05.002 · Cited by 17
Bone signaling pathways and treatment of osteoporosis
Gogakos, A. I., Cheung, M., Bassett, J. H. D., & Williams, G. R. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.38 · Cited by 21
Laroche, M., Couture, G., & Degboé, Y. (2023) · JBMR Plus · doi:10.1002/jbm4.10731 · Cited by 16
Denosumab for osteoporosis in older adults in long‐term care: A randomized trial
Greenspan, S. L., Perera, S., Haeri, N. S., Nace, D. A., & Resnick, N. M. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19260 · Cited by 17
Endocrine and metabolic disorders in HTLV-1 infected patients
Alves, C., & Dourado, L. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70120-3 · Cited by 17
Charcot Pathogenesis: A Study of In Vivo Gene Expression
Connors, J. C., Hardy, M. A., Kishman, L., Botek, G. G., Verdin, C. J., Rao, N. M., & Kingsley, J. D. (2018) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2018.03.023 · Cited by 18
Osteoporosis senil: una actualización
Alonso‐Bouzón, C., & Duque, G. (2011) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2011.02.010 · Cited by 23
Jang, G. R., Kaufman, A., Lee, E. W., Hamilton, L. J., Hutton, S., Egbuna, O. I., & Padhi, D. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.33 · Cited by 16
Treatment of Bone Metastases in Patients with Advanced Breast Cancer
Gnant, M., Balić, M., Petru, E., Raunik, W., Singer, C. F., Steger, G. G., Watzke, I. M., & Brodowicz, T. (2012) · Breast Care · doi:10.1159/000338650 · Cited by 16
Urinary γ-glutamyltransferase (GGT) as a potential marker of bone resorption
Asaba, Y., Hiramatsu, K., Matsui, Y., Harada, A., Nimura, Y., Katagiri, N., Kobayashi, T., Takewaka, T., Ito, M., Niida, S., et al. (2006) · Bone · doi:10.1016/j.bone.2006.06.029 · Cited by 23
Dimai, H. P., Pietschmann, P., Resch, H., Preisinger, E., Fahrleitner‐Pammer, A., Dobnig, H., & Klaushofer, K. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0656-x · Cited by 19
Clarke, B. L. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.03.044 · Cited by 16
Lewiecki, E. M., Bilezikian, J. P., Bukata, S. V., Camacho, P. M., Clarke, B. L., McClung, M. R., Miller, P. D., & Shepherd, J. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.01.001 · Cited by 16
Self-citationSoory, M. (2010) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s10928 · Cited by 27
Ramchand, S. K., & Seeman, E. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_354 · Cited by 18
Bona Fide Genetic Associations with Bone Mineral Density
Hirschhorn, J. N., & Gennari, L. (2008) · New England Journal of Medicine · doi:10.1056/nejme0803046 · Cited by 16
Jörg, D. J., Fuertinger, D. H., Cherif, A., Bushinsky, D. A., Mermelstein, A., Raimann, J. G., & Kotanko, P. (2022) · eLife · doi:10.7554/elife.76228 · Cited by 15
Langdahl, B. L., Chung, Y., Plebanski, R., Czerwinski, E. J., Dokoupilová, E., Supronik, J., Rosa, J., Mydlak, A., Rowińska-Osuch, A., Baek, K., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae611 · Cited by 16
Morgans, A. K., & Smith, M. R. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.07.009 · Cited by 20
Normocalcemic primary hyperparathyroidism: Recommendations for management and follow-up
Diaz‐Guerra, G. M., Gimeno, E. J., Reyes‐García, R., Sáez, J. M. G., & Muñoz‐Torres, M. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.10.014 · Cited by 15
Nakatoh, S. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.12.001 · Cited by 15
Suzuki, T., Nakamura, Y., & Kato, H. (2018) · Nutrients · doi:10.3390/nu10030272 · Cited by 15
Persistence of Denosumab Therapy among Patients with Osteoporosis
Kobayashi, K., Ando, K., Machino, M., Morozumi, M., Kanbara, S., Ito, S., Inoue, T., Yamaguchi, H., Ishiguro, N., & Imagama, S. (2020) · Asian Spine Journal · doi:10.31616/asj.2019.0230 · Cited by 15
Devogelaer, J., & Coppin, C. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605040-00004 · Cited by 15
OsteoRheumatology: a new discipline?
Favero, M., Giusti, A., Geusens, P., Goldring, S. R., Lems, W. F., Schett, G. A., & Bianchi, G. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000083 · Cited by 19
Cedeño‐Veloz, B. A., Erviti, J., Gutiérrez‐Valencia, M., Leache, L., Saiz, L. C., García, A. M. R., Latorre, M. S., Ramírez‐Vélez, R., Izquierdo, M., & Martínez‐Velilla, N. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1825-5 · Cited by 14
Evaluation of an association between RANKL and OPG with bone disease in people with cystic fibrosis
Abid, S., Lee, M., Rodich, B., Hook, J. S., Moreland, J. G., Towler, D. A., Maalouf, N. M., Keller, A. E., Ratti, G. A., & Jain, R. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.08.011 · Cited by 14
Egerdie, B., & Fred Saad, C. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.811 · Cited by 16
A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials
Fang, X., Ji, Y., & Tremmel, L. T. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.03.001 · Cited by 14
Muir, V. J., & Scott, L. J. (2010) · BioDrugs · doi:10.2165/11203310-000000000-00000 · Cited by 14
Cutaneous Side Effects of Antiosteoporosis Treatments
Musette, P., Kaufman, J., Rizzoli, R., Cacoub, P., Brandi, M. L., & Reginster, J. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10387202 · Cited by 14
Proceedings of the 2011 Santa Fe Bone Symposium
Lewiecki, E. M., Bilezikian, J. P., Jankowski, L. G., McCloskey, E. V., Miller, P. D., Morgan, S. L., ORWOLL, E. S., & Potts, J. T. J. (2012) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.11.004 · Cited by 14
Self-citationBone Directed Therapies for Prostate Cancer
Bradley, D., Hussain, M., DiPaola, R. S., & Kantoff, P. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.04.035 · Cited by 15
Cheng, B., & Chen, Y. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3447-y · Cited by 14
Vitamin D and K signaling pathways in hepatocellular carcinoma
Louka, M. L., Fawzy, A. M., Naiem, A. M., Elseknedy, M. F., Abdelhalim, A. E., & Abdelghany, M. A. (2017) · Gene · doi:10.1016/j.gene.2017.07.074 · Cited by 14
ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin, E. J., & Raehl, C. L. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070302 · Cited by 15
Wells, G. A., Hsieh, S., Peterson, J., Zheng, C., Kelly, S., Shea, B., & Tugwell, P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub3 · Cited by 16
Persistence and Recurrence of Primary Hyperparathyroidism
Alnajmi, R. A. Y., Ali, D. S., & Khan, A. A. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.101986 · Cited by 13
Ishii, T., Kikuta, J., Kubo, A., & Ishii, M. (2010) · IBMS BoneKEy · doi:10.1138/20100459 · Cited by 13
Biochemical markers of bone turnover in osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00065-4 · Cited by 19
Translational Strategies to Target Metastatic Bone Disease
Pagnotti, G. M., Trivedi, T., & Mohammad, K. S. (2022) · Cells · doi:10.3390/cells11081309 · Cited by 13
Strategies for treatment to prevent fragility fractures in postmenopausal women
Geusens, P. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.001 · Cited by 15
Optimizing bone health in chronic kidney disease
Pelletier, S., & Chapurlat, R. D. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.021 · Cited by 18
Ueki, K., Yamada, S., Tsuchimoto, A., Tokumoto, M., Kumano, T., Kitazono, T., & Tsuruya, K. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.4946 · Cited by 13
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
Corsini, L. R., Fanale, D., Passiglia, F., Incorvaia, L., Gennusa, V., Bazan, V., & Russo, A. D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1550068 · Cited by 13
Chu, G. C., Chung, L. W. K., Gururajan, M., Hsieh, C., Josson, S., Nandana, S., Sung, S.-Y., Wang, R., Wu, B. J., & Zhau, H. E. (2018) · Asian journal of urology · doi:10.1016/j.ajur.2018.11.003 · Cited by 13
Lewiecki, E. M., Bilezikian, J. P., Kagan, R., Krakow, D., McClung, M. R., Miller, P. D., Rush, E. T., Shuhart, C., Watts, N. B., & Yu, E. W.-Y. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.09.006 · Cited by 14
Self-citationBen‐Porat, T., Weiss, R., Khalaileh, A., Gazala, M. A., Kaluti, D., Mintz, Y., Dagan, S. S., Yackobovitch‐Gavan, M., Rottenstreich, A., Brodie, R., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00845-y · Cited by 13
Therapie bei Knochenmarködemsyndrom im Kniegelenk mit Denosumab
Geith, T., Mutschler, W., & Berger, F. F. (2015) · Der Unfallchirurg · doi:10.1007/s00113-014-2692-2 · Cited by 13
Preventing Bone Complications in Advanced Prostate Cancer
Luz, M. A., & Aprikian, A. G. (2010) · Current Oncology · doi:10.3747/co.v17i0.722 · Cited by 13
The osteoporosis revolution marches on
Raisz, L. G. (2007) · Journal of Orthopaedic Science · doi:10.1007/s00776-007-1133-2 · Cited by 14
Denosumab in postmenopausal osteoporosis: what the clinician needs to know
Lewiecki, E. M. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09343221 · Cited by 13
Self-citationTherapeutic Effects ofCortex acanthopanacisAqueous Extract on Bone Metabolism of Ovariectomized Rats
Zhang, Z., Dong, J., Liu, M., Li, Y., Pan, J., Liu, H., Wang, W., Bai, D., Xiang, L., Xiao, G. G., et al. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/492627 · Cited by 13
Lewiecki, E. M., Baron, R., Bilezikian, J. P., Gagel, R. E., Leonard, M. B., Leslie, W. D., McClung, M. R., & Miller, P. D. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.11.003 · Cited by 13
Self-citationLi, F., Li, H., Zhai, Q., Li, F., Wu, T., Sha, X., Zhang, B., Yang, W., Lu, Z., & Tao, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.205 · Cited by 13
Osteoclast polarization and orthodontic tooth movement
Holliday, L. S., Ostrov, D., Tj, W., & Dolce, C. (2009) · Orthodontics and Craniofacial Research · doi:10.1111/j.1601-6343.2009.01443.x · Cited by 16
Bertoldo, F., Eller-Vainicher, C., Fusco, V., Mauceri, R., Pepe, J., Bedogni, A., Palermo, A., Romeo, U., Guglielmi, G., & Campisi, G. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100656 · Cited by 13
Effects of RANKL Knockdown by Virus-like Particle-Mediated RNAi in a Rat Model of Osteoporosis
Hoffmann, D. B., Gruber, J., Böker, K. O., Deppe, D., Sehmisch, S., Schilling, A. F., Lemus-Diaz, N., Komrakova, M., & Schneider, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.06.001 · Cited by 13
Muraoka, H., Ito, K., Hirahara, N., Okada, S., Kondo, T., & Kaneda, T. (2021) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2021.04.003 · Cited by 14
Agarwal, S., Shane, E. J., Lang, T., Shiau, S., Kamanda‐Kosseh, M., Bucovsky, M., Lappe, J. M., Stubby, J., Recker, R. R., Hu, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac232 · Cited by 13
Wadiura, L. I., Butylina, M., Reinprecht, A., Aretin, M., Mischkulnig, M., Gleiß, A., Pietschmann, P., & Kerschan‐Schindl, K. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4694 · Cited by 12
Nosal, B. M., Sakaki, J. R., Macdonald, Z., Mahoney, K. J., Kim, K., Madore, M. P., Thornton, S., Tran, T. D. B., Weinstock, G. M., Lee, E. C., et al. (2022) · Nutrients · doi:10.3390/nu14234971 · Cited by 12
Denosumab for joints and bones
Lewiecki, E. M. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0027-z · Cited by 12
Self-citationHayashi, S., Fukuda, K., Maeda, T., Chinzei, N., Kihara, S., Miura, Y., Sakai, Y., Hashimoto, S., Matsumoto, T., Takayama, K., et al. (2019) · JBMR Plus · doi:10.1002/jbm4.10191 · Cited by 12
Thompson, K., Freitag, L., Styger, U., Camenisch, K., Zeiter, S., Arens, D., Richards, R. G., Moriarty, T. F., & Stadelmann, V. A. (2020) · Journal of Orthopaedic Research® · doi:10.1002/jor.24951 · Cited by 12
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
Shen, J., Ke, Z., Dong, S., Lv, M., Yuan, Y., Song, L., Wu, K., Xu, K., & Hu, Y. (2022) · Medical Science Monitor · doi:10.12659/msm.935491 · Cited by 12
New Strategies for the Treatment of Metastatic Bone Disease
Pearse, R. N. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.010 · Cited by 13
Hiperparatiroidismo primario normocalcémico: recomendaciones acerca del manejo y seguimiento
Diaz‐Guerra, G. M., Gimeno, E. J., Reyes‐García, R., Sáez, J. M. G., & Muñoz‐Torres, M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.01.015 · Cited by 12
Towards the prevention of bone fractures in dialysed patients?
Jadoul, M. Y. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm508 · Cited by 12
Effects of denosumab on peripheral lymphocyte subpopulations
Rossini, M., Viapiana, O., Adami, S., Idolazzi, L., Ghellere, F., Tripi, G., Ortolani, R., Zanotti, R., & Gatti, D. (2015) · Endocrine · doi:10.1007/s12020-015-0723-6 · Cited by 12
Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis
Lewiecki, E. M. (2006) · Women s Health · doi:10.2217/17455057.2.4.517 · Cited by 12
Self-citationEndocrine Therapy and Bone Loss in Breast Cancer: Time to Close in the RANK(L)?
Lønning, P. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0851 · Cited by 13
Lee, H. A., Kim, S., Seo, H., & Kim, S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273510 · Cited by 11
The Structure of Biological Therapeutics
Martin‐Moe, S., Osslund, T., Wang, Y. J., Mahmood, T., Deshpande, R. R., & Hershenson, S. (2010) · Wiley eBooks · doi:10.1002/9780470595886.ch1 · Cited by 11
Kakar, S., Little, D. G., & Einhorn, T. A. (2009) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e3181ac64a0 · Cited by 12
Type 2 17-β Hydroxysteroid Dehydrogenase as a Novel Target for the Treatment of Osteoporosis
Soubhye, J., Alard, I. C., Antwerpen, P. V., & Dufrasne, F. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.74 · Cited by 11
Patel, T. V., & Singh, A. K. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2009.01.003 · Cited by 11
How Long to Treat with Denosumab
Costa, A. G., & Bilezikian, J. P. (2015) · Current Osteoporosis Reports · doi:10.1007/s11914-015-0295-7 · Cited by 11
Effect of Denosumab on Recurrent Giant Cell Reparative Granuloma of the Lumbar Spine
Akeda, K., Kasai, Y., Sakakibara, T., Matsumine, A., Takegami, N., Yamada, J., & Sudo, A. (2015) · Spine · doi:10.1097/brs.0000000000000862 · Cited by 11
Measurement and Clinical Utility of βCTX in Serum and Plasma
Chubb, S. A. P., & Vasikaran, S. D. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.01.003 · Cited by 12
Non-BMD DXA measurements of the hip
Edmondson, C. P., & Schwartz, E. N. (2017) · Bone · doi:10.1016/j.bone.2017.03.050 · Cited by 11
Kumaki, D., Nakamura, Y., Suzuki, T., & Kato, H. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040063 · Cited by 11
Möckel, L. (2020) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-020-01784-5 · Cited by 11
Denosumab-Induced Immune Hepatitis
Ostrovsky, V., Malnick, S. D. H., Ish-Shalom, S., Ziv‐Sokolovskaya, N., Yosepovich, A., & Neuman, M. G. (2021) · Biomedicines · doi:10.3390/biomedicines9010076 · Cited by 11
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.